 |
3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid |
|---|---|
| Trade Name | |
| Orphan Indication | Hereditary angioedema |
| USA Market Approval | USA |
| USA Designation Date | 2014-12-23 00:00:00 |
| Sponsor | BioCryst Pharmaceuticals, Inc.;4505 Emperor Blvd, Suite 200200;Durham, North Carolina, 27703 |
Related Access Program